Austrian team to develop biochip for screening FH (familial hypercholesterolaemia)
This article was originally published in Clinica
Executive Summary
Austrian researchers are developing a biochip for screening over 600 DNA mutations that they claim cause familial hypercholesterolaemia (FH) - an inherited form of high blood cholesterol. Their work follows the publication of a Dutch study which suggested that DNA analysis targeted at relatives of known sufferers is highly effective in screening for the disorder (see Clinica No 942, p 17).
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.